首页> 外文期刊>Current pharmaceutical design >Drug Development for Central Nervous System Diseases Using In vitro Blood-brain Barrier Models and Drug Repositioning
【24h】

Drug Development for Central Nervous System Diseases Using In vitro Blood-brain Barrier Models and Drug Repositioning

机译:中枢神经系统疾病的药物开发使用体外血脑屏障模型和药物重新定位

获取原文
获取原文并翻译 | 示例
           

摘要

An important goal of biomedical research is to translate basic research findings into practical clinical implementation. Despite the advances in the technology used in drug discovery, the development of drugs for central nervous system diseases remains challenging. The failure rate for new drugs targeting important central nervous system diseases is high compared to most other areas of drug discovery. The main reason for the failure is the poor penetration efficacy across the blood-brain barrier. The blood-brain barrier represents the bottleneck in central nervous system drug development and is the most important factor limiting the future growth of neurotherapeutics. Meanwhile, drug repositioning has been becoming increasingly popular and it seems a promising field in central nervous system drug development. In vitro blood-brain barrier models with high predictability are expected for drug development and drug repositioning. In this review, the recent progress of in vitro BBB models and the drug repositioning for central nervous system diseases will be discussed.
机译:生物医学研究的一个重要目标是将基本研究发现转化为实际临床实施。尽管药物发现中使用的技术进步,但中枢神经系统疾病的毒品的发展仍然具有挑战性。与大多数药物发现领域相比,靶向重要的中枢神经系统疾病的新药物的失败率。失败的主要原因是血脑屏障中渗透效果不佳。血脑屏障代表中枢神经系统药物开发的瓶颈,是限制未来神经治疗的增长的最重要因素。同时,药物重新定位一直变得越来越受欢迎,似乎是中枢神经系统药物发展中有希望的领域。预期药物发育和药物重新定位的高可预测性的体外血脑屏障模型。在本综述中,将讨论最近体外BBB模型的进展和中枢神经系统疾病的药物重新定位。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号